SCYNEXIS Announces Launch of Public Offering of Common Stock

Apr 20, 2015

SCYNEXIS, Inc. Reports Full Year 2014 Financial Results

Mar 30, 2015

SCYNEXIS, Inc. to Present at Jefferies 2015 Antibiotic Summit

Mar 12, 2015

SCYNEXIS, Inc. Appoints Steven C. Gilman, Ph.D., to Board of Directors

Feb 27, 2015

SCYNEXIS, Inc. to Present at RBC Capital Markets 2015 Healthcare Conference

Feb 19, 2015

SCYNEXIS Names Marco Taglietti, M.D., Chief Executive Officer

Feb 6, 2015

SCYNEXIS, Inc. Receives FDA Fast Track Designation for Oral Formulation of SCY-078 for the Treatment of Patients With Invasive Fungal Infections

Jan 9, 2015